Unless stated otherwise, the terms used herein shall carry the same meaning as those defined in the earlier announcements dated 7 December 2020.

Reference is made to the announcements dated 7 December 2020 on the MOU and press release in relation to the cooperation between the Company and Zhifei to conduct Phase 3 clinical trials and subsequent commercialisation of Zhifei's COVID-19 Vaccine in Malaysia.

The Board of Directors of the Company wishes to announce that the Company and Zhifei had on today, 8 January 2021, received affirmations of support and assistance from the Ministry of Health Malaysia and Clinical Research Malaysia respectively for the commencement of clinical trials in the country, subject to the existing laws and regulations governing such clinical trials.

The Board is committed to ensure the commencement of the clinical trials in the near future. Should there be any further developments on this matter, the Company will release the necessary announcements in a timely manner to Bursa Malaysia Securities Berhad.

This announcement is dated 8 January 2021.